
Startups & growth Analysis
Editpep develops a nonviral way to deliver CRISPR for brain therapies
Editpep is developing a nonviral way to deliver CRISPR machinery, with brain therapies as its first focus and licensing as a possible commercial route.

MoneyMakers coverage
Page 1 of 1 · 1 report
Dana Foss is CEO and a co-founder of Editpep.
Published reporting on Dana Foss. Entries describe developments as reported on their publication dates.